| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasms | 12 | 2024 | 757 | 2.730 |
Why?
|
| Skin Neoplasms | 5 | 2023 | 220 | 1.990 |
Why?
|
| Hemangioma | 5 | 2023 | 22 | 1.900 |
Why?
|
| Child | 39 | 2025 | 2430 | 1.860 |
Why?
|
| Hypoalbuminemia | 2 | 2024 | 13 | 1.480 |
Why?
|
| Acupressure | 3 | 2018 | 3 | 1.390 |
Why?
|
| Nausea | 3 | 2018 | 50 | 1.370 |
Why?
|
| Antineoplastic Agents | 6 | 2018 | 595 | 1.230 |
Why?
|
| Urogenital Neoplasms | 4 | 2010 | 5 | 1.150 |
Why?
|
| Infant | 15 | 2025 | 1010 | 1.040 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2009 | 42 | 1.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 8 | 2019 | 442 | 1.010 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2019 | 373 | 0.990 |
Why?
|
| Child, Preschool | 17 | 2025 | 1233 | 0.880 |
Why?
|
| Humans | 58 | 2025 | 32262 | 0.880 |
Why?
|
| Nutritional Status | 1 | 2024 | 73 | 0.840 |
Why?
|
| Sarcoma, Kaposi | 2 | 2023 | 9 | 0.750 |
Why?
|
| Hemangioendothelioma | 2 | 2023 | 11 | 0.750 |
Why?
|
| Male | 34 | 2025 | 19429 | 0.700 |
Why?
|
| Body Mass Index | 1 | 2024 | 863 | 0.690 |
Why?
|
| Adolescent | 16 | 2025 | 3509 | 0.680 |
Why?
|
| Complementary Therapies | 3 | 2006 | 44 | 0.650 |
Why?
|
| Propranolol | 4 | 2023 | 17 | 0.620 |
Why?
|
| Cisplatin | 2 | 2018 | 77 | 0.610 |
Why?
|
| Sirolimus | 2 | 2023 | 34 | 0.590 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 2010 | 211 | 0.550 |
Why?
|
| Pneumocystis carinii | 1 | 2018 | 6 | 0.550 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2018 | 7 | 0.550 |
Why?
|
| Antiemetics | 1 | 2017 | 5 | 0.540 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2018 | 69 | 0.530 |
Why?
|
| Wilms Tumor | 4 | 2015 | 15 | 0.530 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2010 | 30 | 0.520 |
Why?
|
| Treatment Outcome | 12 | 2023 | 3408 | 0.520 |
Why?
|
| Vascular Malformations | 3 | 2025 | 11 | 0.510 |
Why?
|
| Melanoma | 1 | 2018 | 166 | 0.510 |
Why?
|
| Female | 26 | 2025 | 19935 | 0.510 |
Why?
|
| Retrospective Studies | 9 | 2024 | 3609 | 0.490 |
Why?
|
| Immunosuppressive Agents | 1 | 2018 | 248 | 0.480 |
Why?
|
| Follow-Up Studies | 7 | 2025 | 2238 | 0.480 |
Why?
|
| Testicular Neoplasms | 3 | 2010 | 14 | 0.480 |
Why?
|
| Liver Neoplasms | 2 | 2015 | 164 | 0.460 |
Why?
|
| Hepatoblastoma | 1 | 2015 | 2 | 0.460 |
Why?
|
| Neuroblastoma | 2 | 2006 | 32 | 0.450 |
Why?
|
| Referral and Consultation | 2 | 2013 | 137 | 0.420 |
Why?
|
| Prognosis | 5 | 2025 | 1529 | 0.420 |
Why?
|
| Rhabdomyosarcoma | 3 | 2009 | 7 | 0.420 |
Why?
|
| Catheter Ablation | 1 | 2015 | 113 | 0.420 |
Why?
|
| Patient Care Team | 2 | 2016 | 123 | 0.410 |
Why?
|
| Leukemia | 3 | 2008 | 38 | 0.400 |
Why?
|
| Pediatrics | 2 | 2013 | 156 | 0.400 |
Why?
|
| Lung Neoplasms | 2 | 2015 | 422 | 0.390 |
Why?
|
| Medical Errors | 1 | 2013 | 34 | 0.390 |
Why?
|
| Checklist | 1 | 2013 | 39 | 0.390 |
Why?
|
| Patient-Centered Care | 1 | 2013 | 75 | 0.380 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2023 | 59 | 0.380 |
Why?
|
| Medical Oncology | 1 | 2013 | 90 | 0.370 |
Why?
|
| Neuroectodermal Tumors, Primitive | 2 | 2003 | 2 | 0.360 |
Why?
|
| Attitude of Health Personnel | 1 | 2013 | 183 | 0.360 |
Why?
|
| Physician-Patient Relations | 1 | 2013 | 179 | 0.360 |
Why?
|
| Physicians | 1 | 2013 | 163 | 0.350 |
Why?
|
| Survival Rate | 3 | 2024 | 892 | 0.340 |
Why?
|
| Vascular Neoplasms | 2 | 2023 | 12 | 0.300 |
Why?
|
| Therapeutic Touch | 1 | 2009 | 9 | 0.290 |
Why?
|
| Chickenpox | 2 | 2005 | 4 | 0.290 |
Why?
|
| Medical Futility | 1 | 2008 | 2 | 0.290 |
Why?
|
| Cerebrospinal Fluid Proteins | 1 | 2008 | 4 | 0.280 |
Why?
|
| Leukocytosis | 1 | 2008 | 8 | 0.280 |
Why?
|
| Arsenicals | 1 | 2008 | 12 | 0.280 |
Why?
|
| Oxides | 1 | 2008 | 17 | 0.280 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2008 | 20 | 0.280 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2008 | 11 | 0.280 |
Why?
|
| Vincristine | 4 | 2023 | 24 | 0.280 |
Why?
|
| Enchondromatosis | 1 | 2008 | 2 | 0.280 |
Why?
|
| Kidney Neoplasms | 4 | 2015 | 200 | 0.270 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2008 | 5 | 0.270 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2008 | 5 | 0.270 |
Why?
|
| Music | 1 | 2008 | 6 | 0.270 |
Why?
|
| Vomiting | 1 | 2008 | 20 | 0.270 |
Why?
|
| Bone Diseases | 1 | 2008 | 15 | 0.270 |
Why?
|
| Parent-Child Relations | 1 | 2008 | 45 | 0.270 |
Why?
|
| Paracentesis | 1 | 2007 | 4 | 0.260 |
Why?
|
| Burkitt Lymphoma | 1 | 2007 | 6 | 0.260 |
Why?
|
| Pleural Effusion | 1 | 2007 | 15 | 0.260 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2008 | 113 | 0.250 |
Why?
|
| Bone Neoplasms | 2 | 2016 | 104 | 0.250 |
Why?
|
| Attitude to Health | 1 | 2008 | 137 | 0.250 |
Why?
|
| Life Style | 2 | 2006 | 394 | 0.240 |
Why?
|
| Methylobacteriaceae | 1 | 2006 | 2 | 0.240 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2006 | 11 | 0.240 |
Why?
|
| Skin Diseases | 1 | 2008 | 135 | 0.240 |
Why?
|
| Catheterization | 1 | 2006 | 55 | 0.240 |
Why?
|
| Plant Preparations | 1 | 2006 | 27 | 0.230 |
Why?
|
| Phytotherapy | 1 | 2006 | 36 | 0.230 |
Why?
|
| Bacteremia | 1 | 2006 | 66 | 0.230 |
Why?
|
| Prednisone | 1 | 2005 | 69 | 0.230 |
Why?
|
| Hospitals, Veterans | 1 | 2025 | 44 | 0.220 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2004 | 17 | 0.220 |
Why?
|
| Energy Metabolism | 1 | 2006 | 153 | 0.210 |
Why?
|
| Catheterization, Central Venous | 1 | 2005 | 62 | 0.210 |
Why?
|
| Serum Albumin | 1 | 2024 | 56 | 0.210 |
Why?
|
| Dietary Supplements | 1 | 2006 | 188 | 0.210 |
Why?
|
| Glucocorticoids | 1 | 2005 | 146 | 0.210 |
Why?
|
| Medulloblastoma | 1 | 2003 | 8 | 0.200 |
Why?
|
| Cerebellar Neoplasms | 1 | 2003 | 11 | 0.200 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 2 | 2018 | 9 | 0.200 |
Why?
|
| Religion | 1 | 2003 | 28 | 0.190 |
Why?
|
| Health Services Accessibility | 1 | 2025 | 242 | 0.190 |
Why?
|
| Mutation | 2 | 2015 | 497 | 0.190 |
Why?
|
| Prospective Studies | 4 | 2023 | 2315 | 0.180 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2012 | 7 | 0.180 |
Why?
|
| Timolol | 1 | 2022 | 1 | 0.180 |
Why?
|
| Testis | 2 | 2016 | 71 | 0.180 |
Why?
|
| Hemophilia A | 1 | 2022 | 22 | 0.170 |
Why?
|
| Combined Modality Therapy | 2 | 2017 | 551 | 0.170 |
Why?
|
| Craniocerebral Trauma | 1 | 2022 | 55 | 0.170 |
Why?
|
| Thoracic Duct | 1 | 2020 | 2 | 0.160 |
Why?
|
| Lymphangiectasis | 1 | 2020 | 5 | 0.160 |
Why?
|
| Lymphatic Abnormalities | 1 | 2020 | 3 | 0.160 |
Why?
|
| Sclerotherapy | 1 | 2020 | 8 | 0.160 |
Why?
|
| Pericardial Effusion | 1 | 2020 | 9 | 0.160 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2022 | 158 | 0.160 |
Why?
|
| Embolization, Therapeutic | 1 | 2020 | 81 | 0.150 |
Why?
|
| Daunorubicin | 2 | 2010 | 27 | 0.150 |
Why?
|
| Cytarabine | 2 | 2010 | 59 | 0.150 |
Why?
|
| Neoplasm Metastasis | 2 | 2015 | 221 | 0.140 |
Why?
|
| Emergency Service, Hospital | 1 | 2022 | 444 | 0.140 |
Why?
|
| Prednisolone | 1 | 2018 | 9 | 0.140 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2018 | 34 | 0.140 |
Why?
|
| Outpatients | 2 | 2008 | 57 | 0.140 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2018 | 71 | 0.140 |
Why?
|
| Cohort Studies | 1 | 2022 | 1839 | 0.130 |
Why?
|
| Single-Blind Method | 1 | 2017 | 192 | 0.130 |
Why?
|
| Respiratory Insufficiency | 1 | 2018 | 60 | 0.130 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 292 | 0.130 |
Why?
|
| Spinal Puncture | 2 | 2008 | 22 | 0.120 |
Why?
|
| Etoposide | 2 | 2008 | 38 | 0.120 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2016 | 28 | 0.120 |
Why?
|
| Cryopreservation | 1 | 2016 | 52 | 0.120 |
Why?
|
| Risk Factors | 2 | 2018 | 3933 | 0.120 |
Why?
|
| Spermatogenesis | 1 | 2016 | 50 | 0.110 |
Why?
|
| Repressor Proteins | 1 | 2015 | 50 | 0.110 |
Why?
|
| Genetic Markers | 1 | 2015 | 124 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 324 | 0.110 |
Why?
|
| Diagnostic Imaging | 1 | 2016 | 89 | 0.110 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 854 | 0.110 |
Why?
|
| Neoplasms, Complex and Mixed | 1 | 2014 | 2 | 0.110 |
Why?
|
| Ribonuclease III | 1 | 2014 | 3 | 0.110 |
Why?
|
| Young Adult | 3 | 2025 | 2643 | 0.110 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2014 | 10 | 0.110 |
Why?
|
| Pituitary Neoplasms | 1 | 2014 | 15 | 0.100 |
Why?
|
| Infant, Newborn | 2 | 2025 | 666 | 0.100 |
Why?
|
| Remission Induction | 3 | 2012 | 92 | 0.100 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 478 | 0.100 |
Why?
|
| Skin Ulcer | 1 | 2012 | 12 | 0.100 |
Why?
|
| Immunoenzyme Techniques | 2 | 2010 | 47 | 0.090 |
Why?
|
| Abnormalities, Multiple | 1 | 2012 | 27 | 0.090 |
Why?
|
| Paresis | 1 | 2012 | 18 | 0.090 |
Why?
|
| Functional Laterality | 1 | 2012 | 64 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 821 | 0.090 |
Why?
|
| Shoulder Pain | 1 | 2012 | 9 | 0.090 |
Why?
|
| Cyclophosphamide | 2 | 2003 | 37 | 0.090 |
Why?
|
| Arthralgia | 1 | 2012 | 29 | 0.090 |
Why?
|
| Ankle Joint | 1 | 2012 | 43 | 0.090 |
Why?
|
| Thioguanine | 1 | 2010 | 2 | 0.080 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2010 | 43 | 0.080 |
Why?
|
| Knee Joint | 1 | 2012 | 127 | 0.080 |
Why?
|
| Recurrence | 2 | 2008 | 286 | 0.080 |
Why?
|
| Injections, Spinal | 1 | 2010 | 119 | 0.080 |
Why?
|
| Tumor Lysis Syndrome | 1 | 2010 | 3 | 0.080 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2010 | 7 | 0.080 |
Why?
|
| Heart Rate | 2 | 2009 | 364 | 0.080 |
Why?
|
| Fatal Outcome | 3 | 2018 | 85 | 0.080 |
Why?
|
| Predictive Value of Tests | 2 | 2012 | 880 | 0.070 |
Why?
|
| Disease Progression | 2 | 2008 | 591 | 0.070 |
Why?
|
| Gene Expression | 1 | 2010 | 346 | 0.070 |
Why?
|
| Gene Expression Profiling | 1 | 2010 | 315 | 0.070 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2008 | 4 | 0.070 |
Why?
|
| Music Therapy | 1 | 2008 | 6 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2008 | 7 | 0.070 |
Why?
|
| Aminoglycosides | 1 | 2008 | 6 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 2008 | 8 | 0.070 |
Why?
|
| Translocation, Genetic | 1 | 2008 | 20 | 0.070 |
Why?
|
| Mitoxantrone | 1 | 2008 | 20 | 0.070 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2008 | 32 | 0.070 |
Why?
|
| Remission, Spontaneous | 1 | 2008 | 14 | 0.070 |
Why?
|
| Thymoma | 1 | 2007 | 7 | 0.070 |
Why?
|
| Thymus Neoplasms | 1 | 2007 | 6 | 0.070 |
Why?
|
| Graft vs Host Disease | 1 | 2008 | 39 | 0.070 |
Why?
|
| Cross-Over Studies | 1 | 2008 | 95 | 0.070 |
Why?
|
| Bone Marrow Transplantation | 1 | 2008 | 68 | 0.070 |
Why?
|
| Adult | 4 | 2025 | 9252 | 0.070 |
Why?
|
| Thoracic Surgery | 1 | 2007 | 6 | 0.070 |
Why?
|
| Pain Measurement | 1 | 2009 | 339 | 0.070 |
Why?
|
| Time Factors | 2 | 2005 | 2203 | 0.070 |
Why?
|
| Cytological Techniques | 1 | 2007 | 17 | 0.070 |
Why?
|
| United States | 3 | 2025 | 4068 | 0.060 |
Why?
|
| Loss of Heterozygosity | 1 | 2007 | 20 | 0.060 |
Why?
|
| Pilot Projects | 1 | 2009 | 553 | 0.060 |
Why?
|
| Radiography | 1 | 2008 | 358 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2022 | 904 | 0.060 |
Why?
|
| Child Health Services | 1 | 2006 | 24 | 0.060 |
Why?
|
| Stress, Psychological | 1 | 2008 | 227 | 0.060 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2006 | 21 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 245 | 0.060 |
Why?
|
| Species Specificity | 1 | 2006 | 98 | 0.060 |
Why?
|
| Minerals | 1 | 2006 | 14 | 0.060 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2006 | 78 | 0.060 |
Why?
|
| Mind-Body Therapies | 1 | 2006 | 10 | 0.060 |
Why?
|
| Neoplasm Staging | 1 | 2007 | 458 | 0.060 |
Why?
|
| Probability | 1 | 2006 | 155 | 0.060 |
Why?
|
| Leukemia, T-Cell | 1 | 2005 | 2 | 0.060 |
Why?
|
| Retinitis | 1 | 2005 | 3 | 0.060 |
Why?
|
| Immunocompromised Host | 1 | 2005 | 53 | 0.060 |
Why?
|
| Vitamins | 1 | 2006 | 70 | 0.060 |
Why?
|
| Health Surveys | 1 | 2006 | 175 | 0.060 |
Why?
|
| Adrenalectomy | 1 | 2004 | 33 | 0.050 |
Why?
|
| Influenza, Human | 1 | 2006 | 121 | 0.050 |
Why?
|
| Thrombosis | 1 | 2005 | 78 | 0.050 |
Why?
|
| Odds Ratio | 1 | 2005 | 455 | 0.050 |
Why?
|
| Lomustine | 1 | 2003 | 2 | 0.050 |
Why?
|
| Self-Help Groups | 1 | 2003 | 11 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2006 | 395 | 0.050 |
Why?
|
| Diet | 1 | 2006 | 383 | 0.050 |
Why?
|
| Radiotherapy | 1 | 2003 | 92 | 0.050 |
Why?
|
| Neurosurgical Procedures | 1 | 2003 | 93 | 0.050 |
Why?
|
| Ambulatory Care Facilities | 1 | 2023 | 83 | 0.050 |
Why?
|
| Genetic Testing | 1 | 2023 | 90 | 0.050 |
Why?
|
| Diphtheria Toxin | 1 | 2002 | 28 | 0.050 |
Why?
|
| Alleles | 1 | 2023 | 250 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2008 | 1423 | 0.050 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2002 | 26 | 0.050 |
Why?
|
| Educational Status | 1 | 2023 | 167 | 0.050 |
Why?
|
| Minority Groups | 1 | 2023 | 81 | 0.050 |
Why?
|
| Social Support | 1 | 2003 | 180 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2002 | 120 | 0.050 |
Why?
|
| Quality of Life | 1 | 2008 | 968 | 0.050 |
Why?
|
| HIV Infections | 1 | 2007 | 450 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2002 | 129 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2003 | 388 | 0.040 |
Why?
|
| Emergency Medical Services | 1 | 2003 | 183 | 0.040 |
Why?
|
| Exercise | 1 | 2006 | 605 | 0.040 |
Why?
|
| Decision Making | 1 | 2023 | 189 | 0.040 |
Why?
|
| Kidney | 1 | 2004 | 521 | 0.040 |
Why?
|
| Dactinomycin | 1 | 1999 | 13 | 0.040 |
Why?
|
| North Carolina | 1 | 2003 | 1300 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 2012 | 500 | 0.030 |
Why?
|
| Tissue Banks | 1 | 2016 | 14 | 0.030 |
Why?
|
| Infertility, Male | 1 | 2016 | 24 | 0.030 |
Why?
|
| Bone and Bones | 1 | 2016 | 91 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2014 | 15 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2014 | 69 | 0.030 |
Why?
|
| Pedigree | 1 | 2014 | 136 | 0.030 |
Why?
|
| Radiography, Thoracic | 1 | 2014 | 40 | 0.030 |
Why?
|
| Middle Aged | 2 | 2025 | 11837 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2015 | 854 | 0.020 |
Why?
|
| Drug Design | 1 | 2013 | 51 | 0.020 |
Why?
|
| Meningomyelocele | 1 | 2012 | 9 | 0.020 |
Why?
|
| Hypospadias | 1 | 2012 | 10 | 0.020 |
Why?
|
| Syndrome | 1 | 2012 | 66 | 0.020 |
Why?
|
| Vasodilator Agents | 1 | 2012 | 62 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 544 | 0.020 |
Why?
|
| Steroids | 1 | 2012 | 35 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 312 | 0.020 |
Why?
|
| Hyperuricemia | 1 | 2010 | 11 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 1211 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2008 | 50 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2008 | 104 | 0.020 |
Why?
|
| Mediastinal Cyst | 1 | 2007 | 3 | 0.020 |
Why?
|
| Affect | 1 | 2008 | 75 | 0.020 |
Why?
|
| Renal Dialysis | 1 | 2010 | 275 | 0.020 |
Why?
|
| Benzamides | 1 | 2007 | 60 | 0.020 |
Why?
|
| Piperazines | 1 | 2007 | 60 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2007 | 77 | 0.020 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2006 | 24 | 0.020 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2006 | 33 | 0.020 |
Why?
|
| Heart Arrest | 1 | 2006 | 42 | 0.010 |
Why?
|
| Bone Marrow | 1 | 2006 | 68 | 0.010 |
Why?
|
| Chickenpox Vaccine | 1 | 2005 | 3 | 0.010 |
Why?
|
| Acyclovir | 1 | 2005 | 14 | 0.010 |
Why?
|
| Pregnancy | 1 | 2008 | 960 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2006 | 212 | 0.010 |
Why?
|
| Antiviral Agents | 1 | 2005 | 107 | 0.010 |
Why?
|
| Diphtheria Toxoid | 1 | 2002 | 2 | 0.010 |
Why?
|
| HL-60 Cells | 1 | 2002 | 14 | 0.010 |
Why?
|
| Vaccination | 1 | 2002 | 156 | 0.010 |
Why?
|
| Aged | 1 | 2002 | 10249 | 0.000 |
Why?
|